This inventor holds 4 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignees: Development Center for Biotechnology, Academia Sinica, Chang Gung Memorial Hospital. Active years: 2016-2025.
Company Filing History:
4 out of 96 
1 out of 726 
1 out of 7 Years Active: 2016-2025
Title: The Innovations of Chuan-Lung Hsu
Introduction
Chuan-Lung Hsu is a prominent inventor based in New Taipei, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the development of innovative antibodies for cancer treatment. With a total of four patents to his name, Hsu's work is at the forefront of medical research.
Latest Patents
Hsu's latest patents include groundbreaking advancements in anti-human PD-L1 antibodies and their applications. One of his notable inventions is an anti-PD-L1 antibody that comprises specific heavy and light chain variable regions, which can be utilized in various therapeutic contexts. Another significant patent involves antibody-drug conjugates containing anti-Globo H antibodies, which are designed to treat cancer by delivering therapeutic agents directly to targeted cells. This immunoconjugate represents a promising approach to enhance the efficacy of cancer treatments.
Career Highlights
Throughout his career, Chuan-Lung Hsu has worked with esteemed organizations such as the Development Center for Biotechnology and Academia Sinica. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to significant advancements in biotechnology.
Collaborations
Hsu has collaborated with notable colleagues, including Cheng-Chou Yu and Shih-Rang Yang. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Chuan-Lung Hsu's contributions to biotechnology and his innovative patents highlight his role as a key figure in the fight against cancer. His work continues to inspire advancements in medical research and treatment options.